Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion

Endocrine-Related Cancer

Volumn 14, Issue 1, 2007, Pages 91-102

  Zatelli, Maria Chiara ^a   Piccin, Daniela ^a   Vignali, Cristina ^a   Tagliati, Federico ^a   Ambrosio, Maria Rosaria ^a   Bondanelli, Marta ^a   Cimino, Vincenzo ^b   Bianchi, Antonio ^b   Schmid, Herbert A ^c   Scanarini, Massimo ^d   Pontecorvi, Alfredo ^b   De Marinis, Laura ^b   Maira, Giulio ^b   Degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FORSKOLIN; PASIREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; HORMONE; LIGAND; MESSENGER RNA; OLIGOPEPTIDE; SOMATOSTATIN RECEPTOR; VASCULOTROPIN A;

ADULT; ALPHA CHAIN; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MALE; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOMA; AGED; CELL SURVIVAL; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; SECRETION;

ADENOMA; ADULT; AGED; CELL SURVIVAL; FEMALE; HORMONES; HUMANS; LIGANDS; MALE; OLIGOPEPTIDES; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249823374     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0026     Document Type: Article

References (38)

1. Adams RL, Adams IP, Lindow SW & Atkin SL 2004 Inhibition of endothelial proliferation by the somatostatin analogue pasireotide. Clinical Endocrinology 61 431-436.
2. Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH & Hagen C 2001 In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clinical Endocrinology 54 23-30.
3. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 146 707-716.
4. Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, Buscail L & Cordelier P 2005 Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Human Gene Therapy 16 1175-1193.
5. Chelly J, Concordet JP, Kaplan JC & Kahn A 1989 Illegitimate transcription: transcription of any gene in any cell type. PNAS 86 2617-2621.
6. Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B & Lombardi G 2000 New medical approaches in pituitary adenomas. Hormone Research 53 76-87.
7. Danesi R, Agen C, Benelli U, Di Paolo A, Nardini D, Bocci G, Basolo F, Campagni A & Del Tacca M 1997 Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clinical Cancer Research 3 265-272.
8. Danila D, Sleiman Haidar JN, Zhang X, Katznelson L, Culler MD & Klibanski A 2001 Somatostatin receptor specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. Journal of Clinical Endocrinology and Metabolism 86 2976-2981.
9. Ferrara N 2001 Role of vascular endothelial growth factor in regulation of physiological angiogenesis. American Journal of Physiology. Cell Physiology 280 C1358-C1366.
10. Gasperi M, Petrini L, Pilosu R, Nardi M, Marcello A, Mastio F, Bartalena L & Martino E 1993 Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. Journal of Endocrinological Investigation 16 541-543.
11. Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S & Susini C 2005 Physiology of somatostatin receptors. Journal of Endocrinological Investigation 28 5-9.
12. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W & Lamberts SW 2005 Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. Journal of Endocrinological Investigation 28 36-42.
13. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S et al. 2006 Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. European Journal of Endocrinology 155 371-379.
14. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW & Korc M 1997 Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clinical Cancer Research 3 1309-1316.
15. Komorowski J, Jankewicz J & Stepien H 2000 Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours. Cytobios 101 151-159.
16. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K & Grossman AB 2001 The expression of the growth hormone secretogogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 86 881-887.
17. Lamberts SW, van der Lely AJ & Hofland LJ 2002 New somatostatin analogs: will they fulfil old promises? European Journal of Endocrinology 146 701-705.
18. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA & Gittoes NJ 2002 Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 87 4238-4244.
19. Patel YC 1997 Molecular pharmacology of somatostatin receptor subtypes. Journal of Endocrinological Investigation 20 348-367.
20. Pawlikowski M, Pisarek H, Kunert-Radek J & Radek A 2003 Immunihistochemical detection of somatostatin receptor subtypes in 'Clinically Nonfunctioning' pituitary adenomas. Endocrine Pathology 14 231-238.
21. Schmid HA & Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 47-50.
22. Seo Y, Baba H, Fukuda T, Takashima M & Sugimachi K 2000 High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 2239-2245.
23. Sharma K, Patel YC & Srikant CB 1996 Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Molecular Endocrinology 10 1688-1696.
24. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD & Melmed S 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Journal of Clinical Investigation 100 2386-2392.
25. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL & Wass JA 2000 Angiogenesis in pituitary adenomas and the normal pituitary gland. Journal of Clinical Endocrinology and Metabolism 85 1159-1162.
26. Vidal S, Oliveira MC, Kovacs K, Scheithauer BW & Lloyd R 2000 Immunolocalization of vascular endothelial growth factor in the GH3 cell line. Cell and Tissue Research 300 83-88.
27. Weckbecker G, Briner U, Lewis I & Bruns C 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143 4123-4130.
28. Weiner RL, Elias KA & Monnet F 1995 Prolactin. In Basic and Clinical Correlates, pp 641-653. Eds RM Macleod, MO Thorner & U Scapagnini. Padova: Liviana Press.
29. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J & Fassler J 1991 Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. Journal of Surgical Research 50 245-251.
30. Yamada S & Takada K 2003 Angiogenesis in pituitary adenomas. Microscopy Research and Technique 60 236-243.
31. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD & degli Uberti EC 2001 Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. Journal of Clinical Endocrinology and Metabolism 86 2161-2169.
32. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M & degli Uberti EC 2002 Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochemical and Biophysical Research Communications 297 821-827.
33. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD & degli Uberti EC 2003a Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. Journal of Clinical Endocrinology and Metabolism 88 2797-2802.
34. Zatelli MC, Piccin D, Bondanelli M, Tagliati F, De Carlo E, Culler MD & degli Uberti EC 2003b An in vivo Octreoscan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro. Hormone and Metabolic Research 35 349-354.
35. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L et al. 2004 Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 89 5181-5188.
36. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A & degli Uberti EC 2005 SHP-1 restrains cell proliferation in medullary thyroid carcinoma. Endocrinology 146 2692-2698.
37. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Pelizzo MR et al. 2006a Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. Journal of Clinical Endocrinology and Metabolism 91 2218-2224.
38. Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M & degli Uberti EC 2006b Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 9 27-34.